February 18, 2018 5:41 PM ET


Company Overview of Visterra, Inc.

Company Overview

Visterra, Inc., a clinical-stage biopharmaceutical company, focuses on applying its Hierotope platform to identify unique disease targets and to design and engineer antibody-based therapies that are intended to be effective as a single-dose administration. Its lead product candidate is VIS410, a monoclonal antibody (mAb) that is in Phase IIa clinical trials for the treatment of hospitalized patients with influenza A. The company also develops VIS513, a mAb for the treatment of dengue. Its early-stage programs include antibody-based programs VIS-FLX for the prevention of influenza A in high-risk populations. Visterra, Inc. has collaboration and license agreements with Massachusetts Institute ...

One Kendall Square

Suite B3301

Cambridge, MA 02139

United States

Founded in 2007

42 Employees





Key Executives for Visterra, Inc.

Chief Executive Officer, President and Director
Age: 58
Founder and Chairman of the Board
Age: 54
Founder and Director
Age: 52
Chief Financial Officer and Chief Operating Officer
Age: 56
Senior Vice President of Business Development & Strategic Planning
Age: 39
Compensation as of Fiscal Year 2017.

Visterra, Inc. Key Developments

Visterra, Inc. Announces Publication in the Journal PLOS Neglected Tropical Diseases Demonstrating Novel Antibody, VIS513, Broadly Neutralizes Antibody-Enhanced Dengue Infection in Preclinical Studies

Visterra, Inc. announced that new preclinical results with VIS513, its novel monoclonal antibody in development for the treatment of dengue, were published online in the journal PLOS Neglected Tropical Diseases (Y. Budigi et al., PLoS Negl Trop Dis 12(2): e0006209. In the paper titled “Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein,” Visterra scientists and scientists at the National University of Singapore (NUS), the Singapore-MIT Alliance for Research and Technology (SMART) Center, and Duke-National University of Singapore (Duke-NUS) describe preclinical data demonstrating that VIS513 potently neutralized dengue virus at clinically relevant viral loads. More importantly, dengue virus neutralization by VIS513 was demonstrated in the presence of natural antibody that can potentially enhance dengue infection and lead to more severe disease. These data support the continued development of VIS513 as a single administration treatment for dengue virus infection.

Visterra, Inc. Presents at BIO One-on-One Partnering™, Jan-07-2018

Visterra, Inc. Presents at BIO One-on-One Partnering™, Jan-07-2018 . Venue: San Francisco, California, United States.

Visterra, Inc. Presents at 2nd Annual Superbugs & Superdrugs USA Conference, Nov-13-2017 04:40 PM

Visterra, Inc. Presents at 2nd Annual Superbugs & Superdrugs USA Conference, Nov-13-2017 04:40 PM. Venue: Iselin, New Jersey, United States. Speakers: Obadiah Plante, Director of Research.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
NYC2012, Inc. United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Visterra, Inc., please visit www.visterrainc.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.